Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and β-haemolytic streptococci collected from western European countries in 2011

Ian Morrissey; Harald Seifert; Rafael Canton; Patrice Nordmann; Stefania Stefani; Alasdair MacGowan; Regina Janes; Daniel Knight; R. Bonnet; C. J. Soussy; R. Courcol; R. Leclercq; R. Zahar; C. Poyart; Y. Rio; W. Pfister; C. Schoerner; F. Albert; E. Jacobs; S. Schubert; R. Mutters; F. J. Schmitz; F. Luzzaro; E. Manso; C. Scarparo; G. Fadda; F. Rossano; G. M. Rossolini; G. P. Gesu; M. P. Landini; L. Martínez; J. L. Pérez; C. Gimeno; Á Pascual; J. Liñares; R. Bartolomé; R. Cisterna; K. Gould; M. Dryden; M. Weinbren; A. Swann; M. Wilcox; G. Moore; J. Andrews; J. Ashby; S. Kaul

doi:10.1093/jac/dks344

Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and β-haemolytic streptococci collected from western European countries in 2011

Ian Morrissey^*, Harald Seifert, Rafael Canton, Patrice Nordmann, Stefania Stefani, Alasdair MacGowan, Regina Janes, Daniel Knight, R. Bonnet, C. J. Soussy, R. Courcol, R. Leclercq, R. Zahar, C. Poyart, Y. Rio, W. Pfister, C. Schoerner, F. Albert, E. Jacobs, S. SchubertR. Mutters, F. J. Schmitz, F. Luzzaro, E. Manso, C. Scarparo, G. Fadda, F. Rossano, G. M. Rossolini, G. P. Gesu, M. P. Landini, L. Martínez, J. L. Pérez, C. Gimeno, Á Pascual, J. Liñares, R. Bartolomé, R. Cisterna, K. Gould, M. Dryden, M. Weinbren, A. Swann, M. Wilcox, G. Moore, J. Andrews, J. Ashby, S. Kaul

^*Corresponding author for this work

RIPL: Lyme

Research output: Contribution to journal › Article › peer-review

33 Citations (Scopus)

Abstract

Objectives: To determine the activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci (VRE) and β-haemolytic streptococci recently isolated from acute bacterial skin and skin structure infections or bacteraemia in western Europe. Methods: Forty-one centres in Spain (8), Italy (9), Germany (8), France (8) and the UK (8) submitted 866 isolates [204 methicillin-resistant Staphylococcus aureus (MRSA), 177 methicillin-resistant coagulase-negative staphylococci (MRCoNS), 101 VRE, 193 Streptococcus agalactiae and 191 Streptococcus pyogenes] that were collected during the first 6 months of 2011. These were re-identified and susceptibilities to oritavancin and comparators were determined. Results: Oritavancin was very active against MRSA (MIC₅₀/MIC₉₀ 0.03/0.06 mg/L), MRCoNS (0.06/0.12 mg/L), VRE (0.03/0.06 mg/L), S. agalactiae (0.03/0.06 mg/L) and S. pyogenes (0.06/0.25 mg/L). The highest oritavancin MIC observed was 0.25 mg/L (species were S. aureus, Staphylococcus epidermidis, Staphylococcus hominis, S. agalactiae, S. pyogenes and Enterococcus faecalis). Conclusions: These data from recently collected Gram-positive bacteria in western Europe confirm the potent in vitro activity of oritavancin against a wide range of resistant MRSA, MRCoNS and VRE isolates, including ones resistant to newer agents.

Original language	English
Pages (from-to)	164-167
Number of pages	4
Journal	Journal of Antimicrobial Chemotherapy
Volume	68
Issue number	1
DOIs	https://doi.org/10.1093/jac/dks344
Publication status	Published - Jan 2013

Bibliographical note

Funding Information:
I. M. is a former employee of Quotient Bioresearch Ltd, which received funding to carry out the laboratory work from The Medicines Company and has received similar funding for laboratory work and consultancy from numerous other pharmaceutical companies. I. M.’s current employer is IHMA Europe Sàrl. H. S. has received research funding from Basilea, Novartis and Pfizer, has been a consultant for Astellas, AstraZeneca, Janssen-Cilag, Novartis and Wyeth, and has served on the speakers’ bureaus of Astellas, Bayer, Gilead, Infectopharm, Janssen-Cilag, MSD, Novartis, Oxoid and Pfizer. R. C. has received research funding from Novartis and has participated in educational symposia organized by Novartis and Pfizer. S. S. has received research funding from Novartis and Pfizer, has been a consultant for Roche, Novartis and Pfizer, and has served on the speakers’ bureaus of Novartis, BD and Pfizer. P. N., A. M., R. J. and D. K.: none to declare.

Funding Information:
This work was supported by educational/research grants from The Medicines Company.

Keywords

Europe
Gram-positive bacteria
Lipoglycopeptides

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/jac/dks344

Cite this

Morrissey, I., Seifert, H., Canton, R., Nordmann, P., Stefani, S., MacGowan, A., Janes, R., Knight, D., Bonnet, R., Soussy, C. J., Courcol, R., Leclercq, R., Zahar, R., Poyart, C., Rio, Y., Pfister, W., Schoerner, C., Albert, F., Jacobs, E., ... Kaul, S. (2013). Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and β-haemolytic streptococci collected from western European countries in 2011. Journal of Antimicrobial Chemotherapy, 68(1), 164-167. https://doi.org/10.1093/jac/dks344

@article{0bddad28ed804c85b7557c2575d9bd48,

title = "Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and β-haemolytic streptococci collected from western European countries in 2011",

abstract = "Objectives: To determine the activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci (VRE) and β-haemolytic streptococci recently isolated from acute bacterial skin and skin structure infections or bacteraemia in western Europe. Methods: Forty-one centres in Spain (8), Italy (9), Germany (8), France (8) and the UK (8) submitted 866 isolates [204 methicillin-resistant Staphylococcus aureus (MRSA), 177 methicillin-resistant coagulase-negative staphylococci (MRCoNS), 101 VRE, 193 Streptococcus agalactiae and 191 Streptococcus pyogenes] that were collected during the first 6 months of 2011. These were re-identified and susceptibilities to oritavancin and comparators were determined. Results: Oritavancin was very active against MRSA (MIC50/MIC90 0.03/0.06 mg/L), MRCoNS (0.06/0.12 mg/L), VRE (0.03/0.06 mg/L), S. agalactiae (0.03/0.06 mg/L) and S. pyogenes (0.06/0.25 mg/L). The highest oritavancin MIC observed was 0.25 mg/L (species were S. aureus, Staphylococcus epidermidis, Staphylococcus hominis, S. agalactiae, S. pyogenes and Enterococcus faecalis). Conclusions: These data from recently collected Gram-positive bacteria in western Europe confirm the potent in vitro activity of oritavancin against a wide range of resistant MRSA, MRCoNS and VRE isolates, including ones resistant to newer agents.",

keywords = "Europe, Gram-positive bacteria, Lipoglycopeptides",

author = "Ian Morrissey and Harald Seifert and Rafael Canton and Patrice Nordmann and Stefania Stefani and Alasdair MacGowan and Regina Janes and Daniel Knight and R. Bonnet and Soussy, {C. J.} and R. Courcol and R. Leclercq and R. Zahar and C. Poyart and Y. Rio and W. Pfister and C. Schoerner and F. Albert and E. Jacobs and S. Schubert and R. Mutters and Schmitz, {F. J.} and F. Luzzaro and E. Manso and C. Scarparo and G. Fadda and F. Rossano and Rossolini, {G. M.} and Gesu, {G. P.} and Landini, {M. P.} and L. Mart{\'i}nez and P{\'e}rez, {J. L.} and C. Gimeno and {\'A} Pascual and J. Li{\~n}ares and R. Bartolom{\'e} and R. Cisterna and K. Gould and M. Dryden and M. Weinbren and A. Swann and M. Wilcox and G. Moore and J. Andrews and J. Ashby and S. Kaul",

note = "Funding Information: I. M. is a former employee of Quotient Bioresearch Ltd, which received funding to carry out the laboratory work from The Medicines Company and has received similar funding for laboratory work and consultancy from numerous other pharmaceutical companies. I. M.{\textquoteright}s current employer is IHMA Europe S{\`a}rl. H. S. has received research funding from Basilea, Novartis and Pfizer, has been a consultant for Astellas, AstraZeneca, Janssen-Cilag, Novartis and Wyeth, and has served on the speakers{\textquoteright} bureaus of Astellas, Bayer, Gilead, Infectopharm, Janssen-Cilag, MSD, Novartis, Oxoid and Pfizer. R. C. has received research funding from Novartis and has participated in educational symposia organized by Novartis and Pfizer. S. S. has received research funding from Novartis and Pfizer, has been a consultant for Roche, Novartis and Pfizer, and has served on the speakers{\textquoteright} bureaus of Novartis, BD and Pfizer. P. N., A. M., R. J. and D. K.: none to declare. Funding Information: This work was supported by educational/research grants from The Medicines Company.",

year = "2013",

month = jan,

doi = "10.1093/jac/dks344",

language = "English",

volume = "68",

pages = "164--167",

journal = "Journal of Antimicrobial Chemotherapy",

issn = "0305-7453",

publisher = "Oxford University Press",

number = "1",

}

Morrissey, I, Seifert, H, Canton, R, Nordmann, P, Stefani, S, MacGowan, A, Janes, R, Knight, D, Bonnet, R, Soussy, CJ, Courcol, R, Leclercq, R, Zahar, R, Poyart, C, Rio, Y, Pfister, W, Schoerner, C, Albert, F, Jacobs, E, Schubert, S, Mutters, R, Schmitz, FJ, Luzzaro, F, Manso, E, Scarparo, C, Fadda, G, Rossano, F, Rossolini, GM, Gesu, GP, Landini, MP, Martínez, L, Pérez, JL, Gimeno, C, Pascual, Á, Liñares, J, Bartolomé, R, Cisterna, R, Gould, K, Dryden, M, Weinbren, M, Swann, A, Wilcox, M, Moore, G, Andrews, J, Ashby, J & Kaul, S 2013, 'Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and β-haemolytic streptococci collected from western European countries in 2011', Journal of Antimicrobial Chemotherapy, vol. 68, no. 1, pp. 164-167. https://doi.org/10.1093/jac/dks344

Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and β-haemolytic streptococci collected from western European countries in 2011. / Morrissey, Ian; Seifert, Harald; Canton, Rafael et al.
In: Journal of Antimicrobial Chemotherapy, Vol. 68, No. 1, 01.2013, p. 164-167.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and β-haemolytic streptococci collected from western European countries in 2011

AU - Morrissey, Ian

AU - Seifert, Harald

AU - Canton, Rafael

AU - Nordmann, Patrice

AU - Stefani, Stefania

AU - MacGowan, Alasdair

AU - Janes, Regina

AU - Knight, Daniel

AU - Bonnet, R.

AU - Soussy, C. J.

AU - Courcol, R.

AU - Leclercq, R.

AU - Zahar, R.

AU - Poyart, C.

AU - Rio, Y.

AU - Pfister, W.

AU - Schoerner, C.

AU - Albert, F.

AU - Jacobs, E.

AU - Schubert, S.

AU - Mutters, R.

AU - Schmitz, F. J.

AU - Luzzaro, F.

AU - Manso, E.

AU - Scarparo, C.

AU - Fadda, G.

AU - Rossano, F.

AU - Rossolini, G. M.

AU - Gesu, G. P.

AU - Landini, M. P.

AU - Martínez, L.

AU - Pérez, J. L.

AU - Gimeno, C.

AU - Pascual, Á

AU - Liñares, J.

AU - Bartolomé, R.

AU - Cisterna, R.

AU - Gould, K.

AU - Dryden, M.

AU - Weinbren, M.

AU - Swann, A.

AU - Wilcox, M.

AU - Moore, G.

AU - Andrews, J.

AU - Ashby, J.

AU - Kaul, S.

N1 - Funding Information: I. M. is a former employee of Quotient Bioresearch Ltd, which received funding to carry out the laboratory work from The Medicines Company and has received similar funding for laboratory work and consultancy from numerous other pharmaceutical companies. I. M.’s current employer is IHMA Europe Sàrl. H. S. has received research funding from Basilea, Novartis and Pfizer, has been a consultant for Astellas, AstraZeneca, Janssen-Cilag, Novartis and Wyeth, and has served on the speakers’ bureaus of Astellas, Bayer, Gilead, Infectopharm, Janssen-Cilag, MSD, Novartis, Oxoid and Pfizer. R. C. has received research funding from Novartis and has participated in educational symposia organized by Novartis and Pfizer. S. S. has received research funding from Novartis and Pfizer, has been a consultant for Roche, Novartis and Pfizer, and has served on the speakers’ bureaus of Novartis, BD and Pfizer. P. N., A. M., R. J. and D. K.: none to declare. Funding Information: This work was supported by educational/research grants from The Medicines Company.

PY - 2013/1

Y1 - 2013/1

N2 - Objectives: To determine the activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci (VRE) and β-haemolytic streptococci recently isolated from acute bacterial skin and skin structure infections or bacteraemia in western Europe. Methods: Forty-one centres in Spain (8), Italy (9), Germany (8), France (8) and the UK (8) submitted 866 isolates [204 methicillin-resistant Staphylococcus aureus (MRSA), 177 methicillin-resistant coagulase-negative staphylococci (MRCoNS), 101 VRE, 193 Streptococcus agalactiae and 191 Streptococcus pyogenes] that were collected during the first 6 months of 2011. These were re-identified and susceptibilities to oritavancin and comparators were determined. Results: Oritavancin was very active against MRSA (MIC50/MIC90 0.03/0.06 mg/L), MRCoNS (0.06/0.12 mg/L), VRE (0.03/0.06 mg/L), S. agalactiae (0.03/0.06 mg/L) and S. pyogenes (0.06/0.25 mg/L). The highest oritavancin MIC observed was 0.25 mg/L (species were S. aureus, Staphylococcus epidermidis, Staphylococcus hominis, S. agalactiae, S. pyogenes and Enterococcus faecalis). Conclusions: These data from recently collected Gram-positive bacteria in western Europe confirm the potent in vitro activity of oritavancin against a wide range of resistant MRSA, MRCoNS and VRE isolates, including ones resistant to newer agents.

AB - Objectives: To determine the activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci (VRE) and β-haemolytic streptococci recently isolated from acute bacterial skin and skin structure infections or bacteraemia in western Europe. Methods: Forty-one centres in Spain (8), Italy (9), Germany (8), France (8) and the UK (8) submitted 866 isolates [204 methicillin-resistant Staphylococcus aureus (MRSA), 177 methicillin-resistant coagulase-negative staphylococci (MRCoNS), 101 VRE, 193 Streptococcus agalactiae and 191 Streptococcus pyogenes] that were collected during the first 6 months of 2011. These were re-identified and susceptibilities to oritavancin and comparators were determined. Results: Oritavancin was very active against MRSA (MIC50/MIC90 0.03/0.06 mg/L), MRCoNS (0.06/0.12 mg/L), VRE (0.03/0.06 mg/L), S. agalactiae (0.03/0.06 mg/L) and S. pyogenes (0.06/0.25 mg/L). The highest oritavancin MIC observed was 0.25 mg/L (species were S. aureus, Staphylococcus epidermidis, Staphylococcus hominis, S. agalactiae, S. pyogenes and Enterococcus faecalis). Conclusions: These data from recently collected Gram-positive bacteria in western Europe confirm the potent in vitro activity of oritavancin against a wide range of resistant MRSA, MRCoNS and VRE isolates, including ones resistant to newer agents.

KW - Europe

KW - Gram-positive bacteria

KW - Lipoglycopeptides

UR - http://www.scopus.com/inward/record.url?scp=84871183386&partnerID=8YFLogxK

U2 - 10.1093/jac/dks344

DO - 10.1093/jac/dks344

M3 - Article

C2 - 22941898

AN - SCOPUS:84871183386

SN - 0305-7453

VL - 68

SP - 164

EP - 167

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

IS - 1

ER -

Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and β-haemolytic streptococci collected from western European countries in 2011

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this